AUTHOR=Liu Zong-Han , Sun Ju-Xian , Feng Jin-Kai , Yang Shi-Ye , Chen Zhen-Hua , Liu Chang , Chai Zong-Tao , Mao Fei-Fei , Guo Wei-Xing , Shi Jie , Cheng Shu-Qun 

TITLE=Prognostic Comparison Between Liver Resection and Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma Patients With Bile Duct Tumor Thrombus: A Propensity-Score Matching Analysis

JOURNAL=Frontiers in Oncology

VOLUME=Volume 12 - 2022

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.835559

DOI=10.3389/fonc.2022.835559

ISSN=2234-943X

ABSTRACT=Abstract
Background: Hepatocellular carcinoma (HCC) with bile duct tumor thrombus (BDTT) is rare. The aim of this study is to evaluate the long-term prognosis of liver resection (LR) versus transcatheter arterial chemoembolization (TACE) in these patients.
Methods: Data from HCC patients with BDTT who underwent liver resection and TACE were analyzed respectively. Propensity score matching (PSM) analysis was performed in these patients.
Results:145 HCC patients with BDTT were divided into two groups: the LR group (n=105) and the TACE group (n=40). The median OS in the LR group was 8.0 months longer than that in the TACE group before PSM (21.0 vs. 13.0 months, P<0.001) and 9.0 months longer after PSM (20.0 vs. 11.0 months, P<0.001). The median DFS in the LR group was 3.5 months longer than that in the TACE group before PSM (7.0 vs. 3.5 months, P=0.007) and 5 months longer after PSM (7.0 vs. 2.0 months, P=0.007).
Conclusion: If surgery is technically feasible, liver resection provides better prognosis for HCC patients with BDTT compared with TACE.